Multi-Variant Pathway Association Analysis Reveals the Importance of Genetic Determinants of Estrogen Metabolism in Breast and Endometrial Cancer Susceptibility

English version České info

Despite the central role of estrogen exposure in breast and endometrial cancer development and numerous studies of genes in the estrogen metabolic pathway, polymorphisms within the pathway have not been consistently associated with these cancers. We posit that this is due to the complexity of multiple weak genetic effects within the metabolic pathway that can only be effectively detected through multi-variant analysis. We conducted a comprehensive association analysis of the estrogen metabolic pathway by interrogating 239 tagSNPs within 35 genes of the pathway in three tumor samples. The discovery sample consisted of 1,596 breast cancer cases, 719 endometrial cancer cases, and 1,730 controls from Sweden; and the validation sample included 2,245 breast cancer cases and 1,287 controls from Finland. We performed admixture maximum likelihood (AML)–based global tests to evaluate the cumulative effect from multiple SNPs within the whole metabolic pathway and three sub-pathways for androgen synthesis, androgen-to-estrogen conversion, and estrogen removal. In the discovery sample, although no single polymorphism was significant after correction for multiple testing, the pathway-based AML global test suggested association with both breast (p_global = 0.034) and endometrial (p_global = 0.052) cancers. Further testing revealed the association to be focused on polymorphisms within the androgen-to-estrogen conversion sub-pathway, for both breast (p_global = 0.008) and endometrial cancer (p_global = 0.014). The sub-pathway association was validated in the Finnish sample of breast cancer (p_global = 0.015). Further tumor subtype analysis demonstrated that the association of the androgen-to-estrogen conversion sub-pathway was confined to postmenopausal women with sporadic estrogen receptor positive tumors (p_global = 0.0003). Gene-based AML analysis suggested CYP19A1 and UGT2B4 to be the major players within the sub-pathway. Our study indicates that the composite genetic determinants related to the androgen–estrogen conversion are important for the induction of two hormone-associated cancers, particularly for the hormone-driven breast tumour subtypes.

Vyšlo v časopise: Multi-Variant Pathway Association Analysis Reveals the Importance of Genetic Determinants of Estrogen Metabolism in Breast and Endometrial Cancer Susceptibility. PLoS Genet 6(7): e32767. doi:10.1371/journal.pgen.1001012
Kategorie: Research Article
prolekare.web.journal.doi_sk: https://doi.org/10.1371/journal.pgen.1001012

Souhrn

Zdroje

1. DohertyJA

WeissNS

FreemanRJ

DightmanDA

ThorntonPJ

2005 Genetic factors in catechol estrogen metabolism in relation to the risk of endometrial cancer. Cancer Epidemiol Biomarkers Prev 14 357 366

2. HuangCS

ChernHD

ChangKJ

ChengCW

HsuSM

1999 Breast cancer risk associated with genotype polymorphism of the estrogen-metabolizing genes CYP17, CYP1A1, and COMT: a multigenic study on cancer susceptibility. Cancer Res 59 4870 4875

3. CoxA

DunningAM

Garcia-ClosasM

BalasubramanianS

ReedMW

2007 A common coding variant in CASP8 is associated with breast cancer risk. Nat Genet 39 352 358

4. Le MarchandL

DonlonT

KolonelLN

HendersonBE

WilkensLR

2005 Estrogen metabolism-related genes and breast cancer risk: the multiethnic cohort study. Cancer Epidemiol Biomarkers Prev 14 1998 2003

5. TaoMH

CaiQ

ZhangZF

XuWH

KataokaN

2007 Polymorphisms in the CYP19A1 (aromatase) gene and endometrial cancer risk in Chinese women. Cancer Epidemiol Biomarkers Prev 16 943 949

6. GaudetMM

LaceyJVJr

LissowskaJ

PeplonskaB

BrintonLA

2008 Genetic variation in CYP17 and endometrial cancer risk. Hum Genet 123 155 162

7. ThompsonPA

AmbrosoneC

2000 Molecular epidemiology of genetic polymorphisms in estrogen metabolizing enzymes in human breast cancer. J Natl Cancer Inst Monogr 125 134

8. BersteinLM

ImyanitovEN

KovalevskijAJ

MaximovSJ

VasilyevDA

2004 CYP17 and CYP19 genetic polymorphisms in endometrial cancer: association with intratumoral aromatase activity. Cancer Lett 207 191 196

9. TyrerJ

PharoahPD

EastonDF

2006 The admixture maximum likelihood test: a novel experiment-wise test of association between disease and multiple SNPs. Genet Epidemiol 30 636 643

10. DaddT

WealeME

LewisCM

2009 A critical evaluation of genomic control methods for genetic association studies. Genet Epidemiol 33 290 298

11. BulunSE

ChenD

LuM

ZhaoH

ChengY

2007 Aromatase excess in cancers of breast, endometrium and ovary. J Steroid Biochem Mol Biol 106 81 96

12. WangK

LiM

BucanM

2007 Pathway-Based Approaches for Analysis of Genomewide Association Studies. Am J Hum Genet 81

13. PharoahPD

TyrerJ

DunningAM

EastonDF

PonderBA

2007 Association between common variation in 120 candidate genes and breast cancer risk. PLoS Genet 3 e42 doi:10.1371/journal.pgen.0030042

14. LinNU

WinerEP

2008 Advances in adjuvant endocrine therapy for postmenopausal women. J Clin Oncol 26 798 805

15. Early Breast Cancer Trialists' Collaborative Group (EBCTCG) 2005 Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet 365 1687 1717

16. KeyT

ApplebyP

BarnesI

ReevesG

2002 Endogenous sex hormones and breast cancer in postmenopausal women: reanalysis of nine prospective studies. J Natl Cancer Inst 94 606 616

17. MissmerSA

EliassenAH

BarbieriRL

HankinsonSE

2004 Endogenous estrogen, androgen, and progesterone concentrations and breast cancer risk among postmenopausal women. J Natl Cancer Inst 96 1856 1865

18. MaH

BernsteinL

PikeMC

UrsinG

2006 Reproductive factors and breast cancer risk according to joint estrogen and progesterone receptor status: a meta-analysis of epidemiological studies. Breast Cancer Res 8 R43

19. Clavel-ChapelonF

2002 Differential effects of reproductive factors on the risk of pre- and postmenopausal breast cancer. Results from a large cohort of French women. Br J Cancer 86 723 727

20. ShantakumarS

TerryMB

TeitelbaumSL

BrittonJA

MillikanRC

2007 Reproductive factors and breast cancer risk among older women. Breast Cancer Res Treat 102 365 374

21. HamiltonAS

MackTM

2003 Puberty and genetic susceptibility to breast cancer in a case-control study in twins. N Engl J Med 348 2313 2322

22. WeiderpassE

AdamiHO

BaronJA

MagnussonC

BergstromR

1999 Risk of endometrial cancer following estrogen replacement with and without progestins. J Natl Cancer Inst 91 1131 1137

23. MagnussonC

BaronJA

CorreiaN

BergstromR

AdamiHO

1999 Breast-cancer risk following long-term oestrogen- and oestrogen-progestin-replacement therapy. Int J Cancer 81 339 344

24. SyrjakoskiK

VahteristoP

EerolaH

TamminenA

KivinummiK

2000 Population-based study of BRCA1 and BRCA2 mutations in 1035 unselected Finnish breast cancer patients. J Natl Cancer Inst 92 1529 1531

25. KilpivaaraO

BartkovaJ

EerolaH

SyrjakoskiK

VahteristoP

2005 Correlation of CHEK2 protein expression and c.1100delC mutation status with tumor characteristics among unselected breast cancer patients. Int J Cancer 113 575 580

26. FagerholmR

HofstetterB

TommiskaJ

AaltonenK

VrtelR

2008 NAD(P)H:quinone oxidoreductase 1 NQO1*2 genotype (P187S) is a strong prognostic and predictive factor in breast cancer. Nat Genet 40 844 853

27. EerolaH

BlomqvistC

PukkalaE

PyrhonenS

NevanlinnaH

2000 Familial breast cancer in southern Finland: how prevalent are breast cancer families and can we trust the family history reported by patients? Eur J Cancer 36 1143 1148

28. VehmanenP

FriedmanLS

EerolaH

McClureM

WardB

1997 Low proportion of BRCA1 and BRCA2 mutations in Finnish breast cancer families: evidence for additional susceptibility genes. Hum Mol Genet 6 2309 2315

29. VahteristoP

BartkovaJ

EerolaH

SyrjakoskiK

OjalaS

2002 A CHEK2 genetic variant contributing to a substantial fraction of familial breast cancer. Am J Hum Genet 71 432 438

30. VahteristoP

EerolaH

TamminenA

BlomqvistC

NevanlinnaH

2001 A probability model for predicting BRCA1 and BRCA2 mutations in breast and breast-ovarian cancer families. Br J Cancer 84 704 708

31. EastonDF

PooleyKA

DunningAM

PharoahPD

ThompsonD

2007 Genome-wide association study identifies novel breast cancer susceptibility loci. Nature 447 1087 1093

32. DunningAM

HealeyCS

BaynesC

MaiaAT

ScollenS

2009 Association of ESR1 gene tagging SNPs with breast cancer risk. Hum Mol Genet 18 1131 1139

33. AhmedS

ThomasG

GhoussainiM

HealeyCS

HumphreysMK

2009 Newly discovered breast cancer susceptibility loci on 3p24 and 17q23.2. Nat Genet 41 585 590

34. IsolaJ

DeVriesS

ChuL

GhazviniS

WaldmanF

1994 Analysis of changes in DNA sequence copy number by comparative genomic hybridization in archival paraffin-embedded tumor samples. Am J Pathol 145 1301 1308

35. QinZS

NiuT

LiuJS

2002 Partition-ligation-expectation-maximization algorithm for haplotype inference with single-nucleotide polymorphisms. Am J Hum Genet 71 1242 1247

36. StramDO

HaimanCA

HirschhornJN

AltshulerD

KolonelLN

2003 Choosing haplotype-tagging SNPS based on unphased genotype data using a preliminary sample of unrelated subjects with an example from the Multiethnic Cohort Study. Hum Hered 55 27 36

37. GabrielSB

SchaffnerSF

NguyenH

MooreJM

RoyJ

2002 The structure of haplotype blocks in the human genome. Science 296 2225 2229

38. WealeME

DepondtC

MacdonaldSJ

SmithA

LaiPS

2003 Selection and evaluation of tagging SNPs in the neuronal-sodium-channel gene SCN1A: implications for linkage-disequilibrium gene mapping. Am J Hum Genet 73 551 565

39. IlesMM

2006 Obtaining unbiased estimates of tagging SNP performance. Ann Hum Genet 70 254 261